SCHEMBL3720191

SCHEMBL3720191

CC(CO)CON

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3577665 0.81
Bromide SCHEMBL3583647 0.78 CA1 (0.39)
SCHEMBL9394354 0.75 TSHR (0.43)
SCHEMBL991597 0.73
SCHEMBL15358596 0.73 TSHR (0.41)
SCHEMBL1508181 0.73
SCHEMBL3907525 0.73
SCHEMBL8863552 0.73
SCHEMBL1014902 0.73
SCHEMBL1351962 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010121646-A1 HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS NOVARTIS AG (CH) 2010-10-28 WO claimed
US-20090275606-A1 Heterocyclic Compounds as MEK Inhibitors NOVARTIS AG 2009-11-05 US claimed
US-20160207865-A1 PROCESS FOR MANUFACTURING ACRYLIC ACID, ACRYLONITRILE AND 1,4-BUTANEDIOL FROM 1,3-PROPANEDIOL MYRIANT CORPORATION (US) 2016-07-21 US disclosed
WO-2010121646-A1 HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS NOVARTIS AG (CH) 2010-10-28 WO disclosed
US-20090275606-A1 Heterocyclic Compounds as MEK Inhibitors NOVARTIS AG 2009-11-05 US disclosed
WO-2008106204-A1 MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X-PHARMACEUTICALS, INC. (US) 2008-09-04 WO disclosed